Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Acute Myeloid Leukemia: early-phase trial registry
30 of 58 indexed Recurrent Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #244 of 28,707 conditions by registered trial count.
58 US clinical trials · 30 currently recruiting · #244 of 28,707 conditions by registered trial count
Recurrent Acute Myeloid Leukemia: 58 US clinical trials tracked, 30 recruiting.
Recurrent Acute Myeloid Leukemia is the subject of 58 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 25 of these trials.
Enrollment posture brief
Registry condition recurrent-acute-myeloid-leukemia
OPEN 30 | RECR 52% | LATE 0 | EARLY 58 | RANK #244 | SPON 25
Volume-matched condition peers
Nearest open-share peer: Amyloidosis (52% recruiting · 29 trials)
Recurrent Acute Myeloid Leukemia lists 30 open slots (52% of 58 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Acute Myeloid Leukemia is recruiting above its size-band peers.
30 of 58 indexed trials (51.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Acute Myeloid Leukemia research.
M.D. Anderson Cancer Center accounts for 25 of 58 trials (43.1%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 58 trials that report a genuine target (sentinel values excluded). 52 of those (89.7%) plan for fewer than 100 participants.
-
Recurrent Acute Myeloid Leukemia research is mostly interventional.
58 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
58 total, page 2 of 2
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT04250051
CPX-351 Plus Enasidenib for Relapsed AML
Jonsson Comprehensive Cancer Center
NCT03825796
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Children's Oncology Group
NCT04203316
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02397720
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT01822509
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT01904136
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT02509546
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Sumithira Vasu
NCT04220684
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 15 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Acute Myeloid Leukemia page
58 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Recurrent Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Recurrent Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Acute Myeloid Leukemia condition card totals 58 registered trials; most-linked intervention Venetoclax; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.